PriZm Therapeutics is a late-stage clinical biotech company developing therapies for ultra-rare pediatric orphan diseases.
Prizm Therapeutics is focused on advancing innovation that improves human health and well-being. We have assembled a team of world class experts in the study and treatment of AHDS, drug development leaders, and business executives to advance SRW101 for AHDS.
Our team is driven by science, knowledge, and compassion to provide a first-in-class solution for patients and their families who are impacted by AHDS.
SRW101 – Our Lead Program
PriZm Therapeutics has licensed SRW101 from the University of Miami. SRW101 has been used to treat patients under Compassionate Use from the FDA with very positive clinical study results. Our goal is to immediately advance SRW101 into a registration trial and bring it to market for patients with AHDS.
Leadership Team
Kiran Avancha, PhD, RPh
Vivek Kopparthi, MS
Samuel Refetoff, MD
Roy Weiss,
MD, PhD, FACP, FACE
Bernard Cambou,
PhD, MBA
Khemraj Hirani,
PhD, RPh, MBA, RAC
Mark Schwartz, PhD
Ron Wysochansky, MPP
Mustafa Noor, MD, FACP
Corporate Board
Vivek Kopparthi, MS
Kiran Avancha, PhD
Elliot Joseph
